Dr Clara Alsinet-Armengol
This person is a member of Sanger Institute Alumni.
I am a postdoctoral fellow in the Experimental Cancer Genetics team. May main focus is the functional characterization of known and novel cancer genes using human induced Pluripotent Stem Cells and CRISPR-Cas9.
High-throughput sequencing efforts are uncovering the mutation profiles associated to cancer in a comprehensive and unbiased fashion. Nevertheless, further analyses of the identified alterations are necessary to highlight those genes implicated in disease development, as well as, those with therapeutical potential. Recently, the team generated a list of candidate genes commonly lost in cancer based on the analysis of >7500 tumor samples across 28 tissues. To uncover the functional impact of the loss of these genes we are generating a panel of knock-out isogenic iPS cell lines using CRISPR-Cas9 and we will perform high-throughput genetic and drug screenings on these lines. Overall, this study will identify molecular interactions of the selected cancer-related genes thus revealing potential new roles and candidate therapies.
Start of my first Postdoc at the Wellcome Trust Sanger Institute in Cambridge, UK
PhD in Biomedicine from the University of Barcelona
Visiting Researcher at the Icahn School of Medicine at Mount Sinai, New York
Post-Graduate in Molecular and Cellular Biology at the University of Barcelona
Education Aborad Program student at the University of California, Davis
Major in Biotechnology at the Autonomous University of Barcelona